Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 5/20 | 0.54 |
| ▸ | AURKA | O14965 | 6/20 | 0.46 |
| ▸ | SYK | P43405 | 7/20 | 0.45 |
| ▸ | CD63 | P08962 | 1/20 | 0.45 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27180721 | 1.00 | HCRTR2 (0.54) | HCRTR2AURKASYKCD63EPHB4 | |
| SCHEMBL24529669 | 1.00 | HCRTR2 (0.54) | HCRTR2AURKASYKCD63EPHB4 | |
| SCHEMBL27179921 | 0.90 | HCRTR2 (0.53) | HCRTR2AURKASYKCD63EPHB4 | |
| SCHEMBL24529314 | 0.90 | HCRTR2 (0.53) | HCRTR2AURKASYKCD63EPHB4 | |
| SCHEMBL27180949 | 0.88 | HCRTR2 (0.52) | HCRTR2AURKASYKCD63EPHB4 | |
| SCHEMBL24529334 | 0.88 | HCRTR2 (0.52) | HCRTR2AURKASYKCD63EPHB4 | |
| SCHEMBL24529266 | 0.88 | HCRTR2 (0.55) | HCRTR2AURKASYKCD63EPHB4 | |
| SCHEMBL27180734 | 0.88 | HCRTR2 (0.55) | HCRTR2AURKASYKCD63EPHB4 | |
| SCHEMBL24529309 | 0.86 | HCRTR2 (0.53) | HCRTR2AURKASYKCD63EPHB4 | |
| SCHEMBL27181588 | 0.86 | HCRTR2 (0.53) | HCRTR2AURKASYKCD63EPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4262788-A1 | UREA OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-10-25 | — | — | EP | disclosed |
| WO-2022132696-A1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-06-23 | — | — | WO | disclosed |